Ekamol Tantisattamo is a Nephrology physician affiliated with University of California, Irvine. OpenAlex indexes 331 publications with 2,700 citations (h-index 21); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
101 The City Dr S Bldg 30
Orange, CA 928683201
Telephone
714-456-7720Provider last certified this registry record 30 Mar 2023.
Clinical trials
- Dietary Sodium Intake and Blood Pressure in Living Kidney Donors
Sponsor: University of California, Irvine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca UK LimitedProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Calliditas Therapeutics US Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
77.7%Beta blocker21.9%Carvedilol68%Metoprolol Succinate12%Metoprolol Tartrate12%Nebivolol Hcl8%Part D<11 patientsCalcium channel blocker18%Nifedipine Er63%Amlodipine Besylate37%Part D≥25 patients+ 8 more classes in this area
Metabolism & gastrointestinal
9.9%Corticosteroid6.4%Prednisone100%Part D≥12 patientsSGLT2 inhibitor1.8%Jardiance100%Part D<11 patients+ 1 more class in this area
Anti-infectives
7.8%Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor4.4%Valganciclovir Hcl100%Part D≥19 patientsShort-acting sulfonamides3.4%Sulfamethoxazole-Trimethoprim100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Hybrid Telemedicine and In‐Person Care for Kidney Transplant Follow‐Up: A Qualitative Study
Clinical Transplantation
2025 - Diagnosis, management and treatment of the Alport syndrome – 2024 guideline on behalf of ERKNet, ERA and ESPN
Nephrology Dialysis Transplantation
2024 - Nrf2 Pathway and Oxidative Stress as a Common Target for Treatment of Diabetes and Its Comorbidities
International Journal of Molecular Sciences
2024 - Nrf2 Signaling Pathway as a Key to Treatment for Diabetic Dyslipidemia and Atherosclerosis
International Journal of Molecular Sciences
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Susan O’Brien, MD
University of California, Irvine
Steven Potkin, MD
University of California, Irvine
Mitchell Brin, MD
University of California, Irvine
Deborah Wing, MD
University of California, Irvine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”